CMS wants drug prior authorization to move faster and become easier to track

Overview

CMS put a meaningful health-policy issue back in focus on April 10, 2026 when it proposed new rules to modernize drug prior authorization. The agency said payers covered by the rule would face clearer response deadlines, with urgent requests decided within 24 hours and standard requests within 72 hours, while electronic prior authorization would be expanded for drugs covered under medical benefits.

Why this matters to readers

Prior authorization is one of the most frustrating delays in everyday care. Patients often hear that a medicine was prescribed but cannot be dispensed or covered until a separate approval process runs its course. Providers then spend time chasing paperwork, resubmitting notes, and waiting for decisions that may still end in denial. That makes this proposal more than a paperwork story. It is about whether treatment starts quickly or stalls.

CMS is trying to push that process toward faster and more visible handling. The agency’s fact sheet says the rule would add electronic standards for drug prior authorization and require public reporting of new metrics. That could make it easier to compare how payers handle requests instead of leaving the whole process hidden from patients.

What CMS is proposing

The April 10 press release and fact sheet describe three main shifts. First, impacted payers would need to support electronic prior authorization for drugs under a medical benefit beginning October 1, 2027. Second, CMS wants tighter turnaround targets for urgent and standard requests. Third, it wants more transparency around denials, appeals, and usage metrics.

The proposal builds on earlier interoperability rules, but the new step matters because drugs create some of the most visible and emotional prior-authorization fights. A patient waiting on a medication feels the delay much more directly than a debate about technical data exchange rules.

Why the proposal is drawing attention

Hospital and provider groups moved quickly to flag the policy because it could reduce manual burden and help align drug requests with the broader electronic prior-authorization push already under way for non-drug items and services. That supporting response matters. It suggests the proposal is not only a federal paperwork exercise; it is aimed at a bottleneck providers already spend real time and money trying to navigate.

What could change if the rule is finalized

If the deadlines and electronic requirements hold, the biggest gain may be predictability. Patients would still face denials, and payers would still review requests, but the process would become harder to stretch indefinitely. Public reporting could also change the politics of prior authorization by giving employers, patients, and regulators better visibility into which plans are causing the most friction.

There are still open questions. Proposed rules can change, implementation dates are not immediate, and providers will want to know whether payer compliance is strong enough to make the deadlines meaningful in practice.

Why this is the right April health-policy story

This development is current, official, and directly tied to access to care. It does not drift into speculative wellness claims or clinical advice. Instead, it addresses a common barrier between a doctor’s decision and a patient’s treatment. For readers, the practical takeaway is simple: on April 10, 2026, CMS moved to make drug prior authorization faster, more electronic, and more transparent. That is the kind of policy shift that can eventually affect how quickly real care begins.